Therapeutic strategies to overcome taxane resistance in cancer
One of the primary causes of attenuated or loss of efficacy of cancer chemotherapy is the
emergence of multidrug resistance (MDR). Numerous studies have been published …
emergence of multidrug resistance (MDR). Numerous studies have been published …
Cytoskeletal remodeling in cancer
J Aseervatham - Biology, 2020 - mdpi.com
Simple Summary Cell migration is an essential process from embryogenesis to cell death.
This is tightly regulated by numerous proteins that help in proper functioning of the cell. In …
This is tightly regulated by numerous proteins that help in proper functioning of the cell. In …
[HTML][HTML] The circular RNA circ-Ccnb1 dissociates Ccnb1/Cdk1 complex suppressing cell invasion and tumorigenesis
Circular RNAs represent a large class of non-coding RNAs that are extensively expressed in
mammals. However, the functions of circular RNAs are largely unknown. We recently …
mammals. However, the functions of circular RNAs are largely unknown. We recently …
Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway
D Chen, X Lin, C Zhang, Z Liu, Z Chen, Z Li… - Cell Death & …, 2018 - nature.com
Paclitaxel (PTX) is widely used in the front-line chemotherapy for gastric cancer (GC), but
resistance limits its use. Due to the lack of proper models, mechanisms underlying PTX …
resistance limits its use. Due to the lack of proper models, mechanisms underlying PTX …
An integrative human pan-cancer analysis of cyclin-dependent kinase 1 (CDK1)
X Liu, H Wu, Z Liu - Cancers, 2022 - mdpi.com
Simple Summary Cyclin-dependent kinase 1 (CDK1), one of the key regulators of the G2/M
checkpoint, is expressed in many cells and plays an important role in cell cycle control …
checkpoint, is expressed in many cells and plays an important role in cell cycle control …
Ursolic acid reverses the chemoresistance of breast cancer cells to paclitaxel by targeting MiRNA-149-5p/MyD88
F Xiang, Y Fan, Z Ni, Q Liu, Z Zhu, Z Chen… - Frontiers in …, 2019 - frontiersin.org
Paclitaxel (PTX) is widely used as a front-line chemotherapy for breast cancer treatment.
However, its clinical applications are limited by the development of chemoresistance. The …
However, its clinical applications are limited by the development of chemoresistance. The …
TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway
G Qi, H Ma, Y Li, J Peng, J Chen, B Kong - Cell Death & Disease, 2021 - nature.com
High-grade serous ovarian cancer (HGSOC) is the most lethal gynecological malignancy.
However, the molecular mechanisms underlying HGSOC development, progression …
However, the molecular mechanisms underlying HGSOC development, progression …
Generation of two paclitaxel-resistant high-grade serous carcinoma cell lines with increased expression of p-glycoprotein
Debulking surgery followed by chemotherapy are the standard of care for high-grade serous
carcinoma. After an initial good response to treatment, the majority of patients relapse with a …
carcinoma. After an initial good response to treatment, the majority of patients relapse with a …
[HTML][HTML] Gene co-expression network reveals shared modules predictive of stage and grade in serous ovarian cancers
Q Sun, H Zhao, C Zhang, T Hu, J Wu, X Lin, D Luo… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Serous ovarian cancer (SOC) is the most lethal gynecological cancer. Clinical studies have
revealed an association between tumor stage and grade and clinical prognosis …
revealed an association between tumor stage and grade and clinical prognosis …
[HTML][HTML] AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers
H Lemjabbar-Alaoui, CJ Peto, YW Yang… - American Journal of …, 2020 - ncbi.nlm.nih.gov
Abstract Poly (ADP-ribose) polymerase (PARP) has recently emerged as a central mediator
in cancer resistance against numerous anticancer agents to include chemotherapeutic …
in cancer resistance against numerous anticancer agents to include chemotherapeutic …